

# Xiao-Ran Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7618140/publications.pdf>

Version: 2024-02-01

29  
papers

436  
citations

840776

11  
h-index

752698

20  
g-index

33  
all docs

33  
docs citations

33  
times ranked

894  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem-Like Cells. <i>Journal of Cancer</i> , 2016, 7, 408-417.	2.5	73
2	BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. <i>Cancer Letters</i> , 2017, 402, 213-224.	7.2	55
3	Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells. <i>ACS Applied Materials &amp; Interfaces</i> , 2017, 9, 18423-18428.	8.0	47
4	Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1080-1080.	1.6	43
5	Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381982870.	1.9	26
6	Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles. <i>Small Methods</i> , 2018, 2, 1800122.	8.6	20
7	Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. <i>Breast</i> , 2017, 32, 119-125.	2.2	19
8	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 370-382.	2.2	18
9	Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 330-338.	2.2	17
10	Precisely Enumerating Circulating Tumor Cells Utilizing a Multi-Functional Microfluidic Chip and Unique Image Interpretation Algorithm. <i>Theranostics</i> , 2017, 7, 4710-4721.	10.0	14
11	Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 315-326.	2.2	14
12	Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 149-162.	2.2	12
13	Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. <i>Cancer Medicine</i> , 2017, 6, 547-554.	2.8	11
14	Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1059.	1.6	11
15	Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 396-402.	1.1	9
16	Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. <i>Journal of Translational Medicine</i> , 2022, 20, 211.	4.4	8
17	Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4385-4395.	2.0	6
18	Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). <i>Cancer Medicine</i> , 2021, 10, 6089-6098.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Liquid Biospy: Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles (Small Methods) Tj ETQq. 0.784814 rgBT	1.4	0
20	Methylome Variation Predicts Exemestane Resistance in Advanced ER <sup>+</sup> Breast Cancer. Technology in Cancer Research and Treatment, 2020, 19, 153303381989633.	1.9	5
21	Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer. Breast, 2021, 55, 7-15.	2.2	5
22	Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. Cancer Management and Research, 2021, Volume 13, 3303-3316.	1.9	5
23	Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. American Journal of Cancer Research, 2018, 8, 1873-1886.	1.4	5
24	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. Breast Cancer Research and Treatment, 2021, 190, 213-226.	2.5	2
25	Methylation signatures of circulating tumor DNA for hormone therapy response in ER+ breast cancer patients (pts).. Journal of Clinical Oncology, 2017, 35, e12542-e12542.	1.6	0
26	Combined peripheral natural killer (NK) cell and circulating tumor cell (CTC) enumeration to enhance prognostic efficiency in patients (pts) with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2017, 35, 1105-1105.	1.6	0
27	Methylomes variation to predict exemestane resistance in advanced breast cancer.. Journal of Clinical Oncology, 2018, 36, e24029-e24029.	1.6	0
28	Efficacy of platinum-based regimens as the first-line therapy in Chinese patients with advanced TNBC and deleterious BRCA1/2 mutations.. Journal of Clinical Oncology, 2019, 37, e12565-e12565.	1.6	0
29	Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.. Journal of Clinical Oncology, 2022, 40, 535-535.	1.6	0